文献速递乳腺癌

三阴性乳腺癌新辅助化疗后pCR与免疫表型的关联:BrighTNess 3期试验二次分析

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

该研究为BrighTNess 3期随机对照试验的预设二次分析,对482例II-III期三阴性乳腺癌患者治疗前活检组织进行全转录组RNA测序,评估分子亚型、增殖和免疫特征与病理完全缓解(pCR)的关联。

要点

  • 基底样型TNBC的pCR率显著高于非基底样型(52.3% vs 35.4%)。
  • 增殖和免疫特征均为pCR的独立相关因素。
  • 卡铂获益在各分子亚型间无显著差异。

核心结论

  • 三阴性乳腺癌中基底样型和免疫调节亚型pCR率较高,增殖和免疫评分是pCR的独立相关因素,卡铂的pCR获益见于所有分子亚型。

研究设计与样本

  • BrighTNess 3期双盲随机临床试验的预设二次分析,纳入634例II-III期三阴性乳腺癌患者,其中482例有可评估的RNA测序数据。

主要发现

  • 增殖和免疫特征均高于中位数的肿瘤pCR率最高(84/125;67%),均低于中位数的pCR率最低(42/125;34%)。
  • 探索性分析提示CD8+ T细胞浸润较高的肿瘤可能从卡铂添加中获得更大获益。

临床怎么用

  • 基于增殖和免疫特征的评分可能有助于识别pCR概率高的TNBC患者,为治疗升阶或降阶提供参考。

局限性

  • 本文为二次分析,部分患者(482/634)无可用RNA测序数据。
  • 免疫表型与卡铂获益的关联为探索性分析,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adding carboplatin to standard neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) likely benefits a subset of patients; however, determinants of benefit are poorly understood. OBJECTIVE: To define the association of molecular subtype, tumor proliferation, and immunophenotype with benefit of carboplatin added to NAC for patients with stages II to III TNBC. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of a phase 3, double-blind, randomized clinical trial (BrighTNess) that enrolled 634 women across 145 centers in 15 countries. Women with clinical stages II to III TNBC who had undergone pretreatment biopsy were eligible to participate. Whole transcriptome RNA sequencing was performed on the biopsy specimens. The prespecified end point was association of pathologic complete response (pCR) with gene expression-based molecular subtype, with secondary end points investigating established signatures (proliferation, immune) and exploratory analyses of immunophenotype. Data were collected from April 2014 to March 2016. The study analyses were performed from January 2018 to March 2019. INTERVENTIONS: Neoadjuvant chemotherapy with paclitaxel followed by doxorubicin and cyclophosphamide, or this same regimen with carboplatin or carboplatin plus veliparib. MAIN OUTCOMES AND MEASURES: Association of gene expression-based molecular subtype (PAM50 and TNBC subtypes) with pCR. RESULTS: Of the 634 women (median age, 51 [range, 22-78] years) enrolled in BrighTNess, 482 (76%) patients had evaluable RNA sequencing data, with similar baseline characteristics relative to the overall intention-to-treat population. Pathologic complete response was significantly more frequent in PAM50 basal-like vs nonbasal-like cancers overall (202 of 386 [52.3%] vs 34 of 96 [35.4%]; P = .003). Carboplatin benefit was not significantly different in basal-like vs nonbasal-like subgroups (P = .80 for interaction). In multivariable analysis, proliferation (hazard ratio, 0.36; 95% CI, 0.21-0.61; P < .001) and immune (hazard ratio, 0.62; 95% CI, 0.49-0.79; P < .001) signatures were independently associated with pCR. Tumors above the median for proliferation and immune signatures had the highest pCR rate (84 of 125; 67%), while those below the median for both signatures had the lowest pCR rate (42 of 125; 34%). Exploratory gene expression immune analyses suggested that tumors with higher inferred CD8+ T-cell infiltration may receive greater benefit with addition of carboplatin. CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, triple-negative breast cancer subtyping revealed high pCR rates in basal-like and immunomodulatory subsets. Analysis of biological processes related to basal-like and immunomodulatory phenotypes identified tumor cell proliferation and immune scores as independent factors associated with achieving pCR; the benefit of carboplatin on pCR was seen across all molecular subtypes. Further validation of immunophenotype with existing biomarkers may help to escalate or de-escalate therapy for patients with TNBC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02032277.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Filho OM, Stover DG, Asad S, et al. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33599688. doi:10.1001/jamaoncol.2020.7310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。